Bionano Genomics, Inc. (BNGO) — SEC Filings
Bionano Genomics, Inc. (BNGO) — 39 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 22 8-K, 6 10-Q, 4 DEF 14A.
View Bionano Genomics, Inc. on SEC EDGAR
Overview
Bionano Genomics, Inc. (BNGO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Bionano Genomics, Inc. reported a net loss of $8.5 million for the three months ended September 30, 2025, a significant improvement from the $44.2 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $18.5 million, substantially lower than the $
Sentiment Summary
Across 39 filings, the sentiment breakdown is: 3 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Bionano Genomics, Inc. is neutral.
Filing Type Overview
Bionano Genomics, Inc. (BNGO) has filed 6 10-Q, 22 8-K, 1 S-1, 1 8-K/A, 4 DEF 14A, 2 10-K, 2 DEFA14A, 1 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (39)
Risk Profile
Risk Assessment: Of BNGO's 37 recent filings, 3 were flagged as high-risk, 20 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $7,367,000 |
| Net Income | -$8,500,000 |
| EPS | N/A |
| Debt-to-Equity | 0.59 |
| Cash Position | $3,065,000 |
| Operating Margin | N/A |
| Total Assets | $79,062,000 |
| Total Debt | $29,263,000 |
Key Executives
- R. Erik Holmlin, Ph.D.
- Michael J. Mauboussin
- Christopher S. Peetz
Industry Context
Bionano Genomics operates in the rapidly evolving field of genomic analysis, focusing on long-read sequencing technology. The industry is characterized by intense competition from established players and emerging technologies. Key trends include the increasing demand for advanced genomic solutions in research, diagnostics, and personalized medicine, as well as the ongoing development of more efficient and cost-effective sequencing platforms.
Top Tags
material-agreement (9) · governance (7) · financials (7) · filing (6) · proxy-statement (5) · Biotechnology (4) · corporate-governance (4) · 10-Q (4) · 8-k (4) · Going Concern (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $8.5M | Significantly reduced from $44.2M in Q3 2024 |
| Net Loss (9M 2025) | $18.5M | Substantially lower than $91.9M in 9M 2024 |
| Total Revenue (Q3 2025) | $7.4M | Increased from $6.1M in Q3 2024 |
| Product Revenue (Q3 2025) | $6.9M | Increased from $6.0M in Q3 2024 |
| Total Operating Expenses (Q3 2025) | $11.9M | Drastically reduced from $35.5M in Q3 2024 |
| Cash and Cash Equivalents | $3.1M | As of September 30, 2025, down from $9.2M at Dec 31, 2024 |
| Accumulated Deficit | $711.7M | As of September 30, 2025 |
| Cash Used in Operations (9M 2025) | $12.2M | Indicates continued cash burn |
| Reverse Stock Split Ratio | 1-for-60 | Effected on January 24, 2025 |
| Common Shares Outstanding | 9,730,400 | As of September 30, 2025, post-split |
| Shares of Common Stock | 2,032,520 | Maximum number of shares offered in the public offering |
| Pre-Funded Warrants | 2,032,520 | Maximum number of Pre-Funded Warrants offered |
| Shares of Common Stock Issuable | 6,097,560 | Total shares issuable upon exercise of all Warrants and Pre-Funded Warrants |
| Assumed Offering Price | $4.92 | Assumed combined public offering price per share and accompanying Warrants, equal to the closing price on September 10, 2025 |
| Pre-Funded Warrant Exercise Price | $0.0001 | Exercise price per share for each Pre-Funded Warrant |
Frequently Asked Questions
What are the latest SEC filings for Bionano Genomics, Inc. (BNGO)?
Bionano Genomics, Inc. has 39 recent SEC filings from Jan 2024 to Nov 2025, including 22 8-K, 6 10-Q, 4 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BNGO filings?
Across 39 filings, the sentiment breakdown is: 3 bearish, 35 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Bionano Genomics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bionano Genomics, Inc. (BNGO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bionano Genomics, Inc.?
Key financial highlights from Bionano Genomics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BNGO?
The investment thesis for BNGO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bionano Genomics, Inc.?
Key executives identified across Bionano Genomics, Inc.'s filings include R. Erik Holmlin, Ph.D., Michael J. Mauboussin, Christopher S. Peetz.
What are the main risk factors for Bionano Genomics, Inc. stock?
Of BNGO's 37 assessed filings, 3 were flagged high-risk, 20 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Bionano Genomics, Inc.?
Forward guidance and predictions for Bionano Genomics, Inc. are extracted from SEC filings as they are enriched.